Form 4: Equillium Director Bala S Manian Acquires 20,000 Stock Options

Equillium, Inc. Director Bala S Manian has acquired 20,000 stock options with an exercise price of $0.39, granted on May 21, 2025, as part of a compensation package.

Summary

• Bala S Manian, a Director of Equillium, Inc. (EQ), acquired 20,000 Director Stock Options.
• The transaction date for the option grant was May 21, 2025.
• The exercise price for these options is $0.39 per share.
• Each option represents the right to buy one share of Equillium Common Stock.
• The options vest in twelve equal monthly installments commencing on the grant date of May 21, 2025, and will be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
• The expiration date for these options is May 20, 2035.
• Following this transaction, Bala S Manian beneficially owns 20,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard compensation practice, aligning the director's interests with the company's performance, which is generally viewed as a neutral to slightly positive event as it incentivizes long-term value creation.

Positives

• The grant of stock options to a director aligns management's financial interests with those of the shareholders, as the options gain value if the company's stock price increases.
• The options have a long expiration date (May 20, 2035), providing a significant window for potential value realization.

Future Outlook

The stock options granted to Director Bala S Manian will vest in twelve equal monthly installments commencing on the grant date, with full vesting by the date of the Issuer's annual meeting of stockholders following the grant date, indicating a future increase in exercisable options.

Management Comments

• No direct quotes from management were provided in this Form 4 filing; however, the grant of stock options is a common form of executive and director compensation.

Industry Context

The grant of stock options to directors is a standard practice across various industries, particularly in biotechnology and growth-oriented companies, to incentivize long-term performance and align leadership interests with shareholder value creation. This Form 4 filing reflects a routine compensation event for an insider.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a common industry practice.
• Specific comparable companies, projects, or results regarding the size or terms of this particular option grant are not detailed within this Form 4 filing.

Related Party Transactions

• The grant of 20,000 Director Stock Options to Bala S Manian, a director of Equillium, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value, potentially leading to better long-term performance.
• Director (Bala S Manian): Receives equity compensation that provides an incentive tied to the company's stock performance.

Next Steps

• The options will continue to vest in monthly installments following the grant date.
• Bala S Manian may choose to exercise these options at any time after they vest and before their expiration date.

Key Dates

Recommendation

Keywords

Equillium, EQ, Stock Options, Director Compensation, Insider Transaction, Form 4, Beneficial Ownership, Equity Compensation